Cardiac ECM Program

About Ventrix

Founded in 2013, Ventrix is a private, preclinical-stage biotech pioneering ECM-based biotherapeutics. The company's core hypothesis is that delivering tissue-specific extracellular matrix can restart stalled repair processes by providing the essential architectural and biochemical framework for cellular regeneration. Targeting significant unmet needs in cardiovascular repair, Ventrix aims to translate the fundamental biology of the ECM into a new therapeutic modality. As a pre-revenue company, its success hinges on advancing its lead programs through clinical validation.

Therapeutic Areas